Background: Uterine contractions during labour are associated with relative foetal hypoxia. The hypoxia becomes significant when the uterine contractions are abnormal or the labour is prolonged and can lead to fetal distress or birth asphyxia. Prolonged labour occurs when the active phase of labour lasts more than 12 hours and could result from abnormal uterine contractions or a slow cervical dilatation rate (<1cm/hr). Amniotomy and oxytocin augmentation is the standard modality for preventing prolonged labour because it improves uterine contractions. At times, despite good uterine contractions slow progress persists due to cervical smooth muscle spasms which increase the total oxytocin usage and lead to prolonged labour, further worsening intrauterine hypoxia and resulting in foetal distress and birth asphyxia. Drotaverine a musculotropic antispasmodic can relieve smooth muscle spasms. Aim/objective: The study compared the incidence of birth asphyxia following augmentation with oxytocin alone vs oxytocin and drotaverine for slow labour progress.Methods: This study is a single-blinded randomized clinical trial done for eight months. It involves 156 nulliparous parturients at term with slow labour progress, who were randomized into two groups. Each group had 78 parturients who received either oxytocin with placebo or oxytocin with drotaverine. They were monitored till delivery and the incidence of birth asphyxia in both groups was compared. Data obtained were analysed using IBM SPSS version 23 software. The level of significance was set at 0.05.Results: The two groups were similar in their socio-demographic characteristics and mode of delivery. Following augmentation, the incidence of birth asphyxia in the oxytocin-placebo was similar to the oxytocin-drotaverine group(7 (9.0%) vs. 5 (6.4%), p=0.55). Conclusion: The addition of drotaverine to the standard management of dysfunctional labour with oxytocin titration in term nulliparas is not associated with increased adverse neonatal outcomes.